Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Albumin in inhibition of abnormal aggregation of Tau protein

A protein and abnormal technology, applied in the field of biomedicine, can solve problems such as unsatisfactory drug efficacy

Pending Publication Date: 2022-03-15
苏强 +4
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to overcome the above-mentioned deficiencies of the prior art, to provide a kind of Albumin as the application of Tau protein abnormal aggregation-related inhibitors or drugs, to solve the existing clinical traditional Chinese medicine for inhibiting Tau protein abnormal aggregation and treating Tau protein disease Unsatisfactory technical problems

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Albumin in inhibition of abnormal aggregation of Tau protein
  • Application of Albumin in inhibition of abnormal aggregation of Tau protein
  • Application of Albumin in inhibition of abnormal aggregation of Tau protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1: Inhibitory effect of different concentrations of Albumin on Tau R3 protein fibrosis.

[0040] Because heparin sodium induces Tau R3 protein to self-aggregate to form fibers. In order to simulate the abnormal aggregation of Tau protein in the brain to form neurofibrillary tangles, in this example, Tau R3 protein was induced by heparin sodium to aggregate abnormally to form neurofibrillary tangles. Thioflavin T (ThT) can interact with the β-sheet in the aggregated filaments to generate fluorescence, and its fluorescence intensity is positively correlated with the amount of fiber, which can be used for quantitative analysis of protein fiber amount.

[0041] Method: The purchased Tau R3 protein freeze-dried product was precisely weighed, dissolved in PBS, and prepared into a protein solution with a concentration of 1 mM, then diluted to 20 μM with PBS, and the exact concentration was recorded. Accurately weigh Albumin, prepare high-concentration drug mother solu...

Embodiment 2

[0049] Example 2: Transmission electron microscopy experiment of Albumin inhibiting Tau R3 protein fibrosis.

[0050] Methods: The aggregation and fibrosis of Tau R3 treated with Albumin can be visually observed by transmission electron microscope (TEM), which is a strong evidence for the ThT fluorescence experiment. From the ThT experiment in Example 1, collect 10 μL of samples from the control group, Albumin group, and TauR3 group respectively, drop them on the copper grid, settle for 1 min, then absorb the excess samples with filter paper, and then drop 2% uranyl acetate for staining , let stand for 5 minutes, then absorb excess uranyl acetate with filter paper, and let stand for 30 minutes. Place in a transmission electron microscope (JEOL, JEM-1011), observe at an accelerating voltage of 100kV, take pictures and save the images.

[0051] Results: The transmission electron microscope pictures are as follows figure 2 As shown, among them, figure 2 -A is the control gro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of a Tau protein abnormal aggregation inhibitor and a medicine for preventing / treating Tau proteopathy. The invention provides an application of Albumin as an inhibitor for abnormal aggregation of Tau protein, and also provides an application of Albumin in preparation of a medicine for preventing / treating Tau proteopathy. Experiments prove that the Albumin has a relatively strong function of inhibiting the abnormal aggregation of the Tau protein. Therefore, after the Albumin is used as the inhibitor for the abnormal aggregation of the Tau protein, the effect of effectively inhibiting the abnormal aggregation of the Tau protein can be achieved, so that the Tau protein disease caused by the abnormal aggregation of the Tau protein is prevented or treated.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of a drug for inhibiting abnormal aggregation of tau protein and preventing / treating tau protein disease. Background technique [0002] Tau protein is a microtubule-associated protein whose gene is located at position 17 of autosome. The main physiological function of Tau protein is to combine with tubulin to promote its polymerization to form microtubules, maintain microtubule stability, reduce the dissociation of tubulin molecules, and induce microtubule bundling. [0003] Studies have found that many neurodegenerative diseases are related to Tau protein abnormalities, Alzheimer's disease is related to Tau protein phosphorylation and aggregation fibrosis, frontotemporal dementia is related to Tau protein mutations, and also in progressive supranuclear disease. Tau fibrillary tangles are also found in other neurodegenerative diseases such as para...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/38A61P25/28A61P25/00A23L33/17
CPCA61K38/38A61P25/28A61P25/00A23L33/17A23V2002/00A23V2200/322A23V2250/5436
Inventor 苏强王卓然杨铭萱张艳丽李甜
Owner 苏强
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products